Xenium and IMC data in "Spatial Single-Cell Profiling Identifies Immune-Cold Tumor Niches Linked to Early Progression on EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant NSCLC"

Documenti analoghi

• Novel Resistance Mechanisms to Second‐Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC
  di: Fengwu Lin, et al.
  Pubblicazione: (2025)
• Spatial Heterogeneity of PD‐L1 Expression as a Biomarker for Third‐Generation EGFR‐TKI Response in Advanced EGFR‐Mutant NSCLC
  di: Yidan Zhang, et al.
  Pubblicazione: (2025)
• Decoding Brain Metastasis With Liquid Biopsy: Biomarkers and Technologies in EGFR ‐Mutant NSCLC
  di: Yuxiang Sun, et al.
  Pubblicazione: (2026)
• Persist or resist: Immune checkpoint inhibitors in EGFR‐mutated NSCLC
  di: Pengcheng Zhu, et al.
  Pubblicazione: (2024)
• DFT and Molecular Docking Studies of N‐(7‐Indazolyl)benzenesulfonamides as Potential Drugs Targeting EGFR‐Tyrosine Kinase Inhibitors
  di: Aziz Moumad, et al.
  Pubblicazione: (2025)